LIVIVO - Search results -

Search results

Result 1 - 10 of total 68

Search options

Article ; Online: New Landmarks Towards Reducing the Treatment Burden for Patients with a Postchemotherapy Residual Retroperitoneal Mass from Nonseminomatous Germ-cell Testicular Tumors.

Nicolai, Nicola / Nazzani, Sebastiano

European urology oncology

2022 Volume 5, Issue 2, Page(s) 244–245

MeSH term(s)	Humans ; Male ; Neoplasms, Germ Cell and Embryonal/drug therapy ; Testicular Neoplasms/pathology
Language	English
Publishing date	2022-02-17
Publishing country	Netherlands
Document type	Editorial ; Comment
ISSN	2588-9311
ISSN (online)	2588-9311
DOI	10.1016/j.euo.2022.01.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Editorial Comment to Ureteral location is associated with survival outcomes in upper tract urothelial carcinoma: A population-based analysis.

Nazzani, Sebastiano / Nicolai, Nicola

International journal of urology : official journal of the Japanese Urological Association

2020 Volume 27, Issue 11, Page(s) 973

MeSH term(s)	Carcinoma, Transitional Cell/epidemiology ; Humans ; Ureter/surgery
Language	English
Publishing date	2020-08-29
Publishing country	Australia
Document type	Journal Article ; Comment
ZDB-ID	1328401-0
ISSN	1442-2042 ; 0919-8172
ISSN (online)	1442-2042
ISSN	0919-8172
DOI	10.1111/iju.14359
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4460: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 278: Show issues

Order via subito

Details ▾

Article ; Online: Prostate cancer: A valuable tool for prediction of repeat biopsy pathology.

Karakiewicz, Pierre / Nazzani, Sebastiano

Nature reviews. Urology

2017 Volume 15, Issue 3, Page(s) 140–141

MeSH term(s)	Biopsy, Needle ; Humans ; Magnetic Resonance Imaging ; Male ; Nomograms ; Organ Size ; Prostate/diagnostic imaging ; Prostate/pathology ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/diagnosis ; Recurrence ; Risk Assessment ; Ultrasonography
Chemical Substances	Prostate-Specific Antigen (EC 3.4.21.77)
Language	English
Publishing date	2017-12-28
Publishing country	England
Document type	Journal Article
ZDB-ID	2493737-X
ISSN	1759-4820 ; 1759-4812
ISSN (online)	1759-4820
ISSN	1759-4812
DOI	10.1038/nrurol.2017.216
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6030: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Role of immunotherapy in kidney cancer.

Nazzani, Sebastiano / Bazinet, Amélie / Karakiewicz, Pierre I

Current opinion in supportive and palliative care

2018 Volume 12, Issue 3, Page(s) 325–333

Abstract: Purpose of review: To summarize current knowledge on promising immunotherapeutic agents and to provide a brief outline of current use of immunotherapeutic agents in patients with locally advanced or metastatic renal cell carcinoma (RCC).: Recent ... ...

Abstract	Purpose of review: To summarize current knowledge on promising immunotherapeutic agents and to provide a brief outline of current use of immunotherapeutic agents in patients with locally advanced or metastatic renal cell carcinoma (RCC). Recent findings: Immunotherapy with mAbs directed against programed death cell protein 1, programed death-ligand 1 (PD-L1) and cytotoxic T-Lymphocyte Antigen 4 has become new first-line standard of care for moderate and poor-risk metastatic RCC patients. Similarly, the combination immune-oncology treatment and vascular endothelial growth factor (VEGF) mAbs also showed promising results in first-line therapy despite relative data immaturity. Finally, immune-oncology monotherapy (nivolumab) already represents second or third-line standard of care after tyrosine kinase inhibitor failure. Summary: Combination immune-oncology therapy represents the standard of care for management of intermediate-to-poor risk clear cell metastatic RCC. In addition, combination of immune-oncology and anti-VEGF antibody represents a treatment option across all risk levels in patient with elevated PD-L1 expression. Finally, nivolumab is one of two ideal treatment options in second-line clear cell metastatic RCC patients.
MeSH term(s)	Adjuvants, Immunologic/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents, Immunological ; B7-H1 Antigen/antagonists & inhibitors ; Bevacizumab/pharmacology ; Bevacizumab/therapeutic use ; Carcinoma, Renal Cell/pathology ; Carcinoma, Renal Cell/therapy ; Combined Modality Therapy ; Humans ; Immunotherapy/methods ; Ipilimumab/pharmacology ; Ipilimumab/therapeutic use ; Kidney Neoplasms/pathology ; Kidney Neoplasms/therapy ; Neoplasm Metastasis ; Nivolumab/pharmacology ; Nivolumab/therapeutic use ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
Chemical Substances	Adjuvants, Immunologic ; Antibodies, Monoclonal ; Antineoplastic Agents, Immunological ; B7-H1 Antigen ; CD274 protein, human ; Ipilimumab ; Programmed Cell Death 1 Receptor ; Vascular Endothelial Growth Factor A ; Bevacizumab (2S9ZZM9Q9V) ; Nivolumab (31YO63LBSN) ; atezolizumab (52CMI0WC3Y) ; Protein-Tyrosine Kinases (EC 2.7.10.1)
Language	English
Publishing date	2018-07-23
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2633726-5
ISSN	1751-4266 ; 1751-4258
ISSN (online)	1751-4266
ISSN	1751-4258
DOI	10.1097/SPC.0000000000000363
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6946: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Surveillance or Dynamic Sentinel Lymph-Node Biopsy in Low-Risk Clinically N0 Penile Squamous Cell Carcinoma: Single-Institution Real World Data.

Nazzani, Sebastiano / Catanzaro, Mario / Bruniera, Martina / Torelli, Tullio / Macchi, Alberto / Stagni, Silvia / Tesone, Antonio / Silvani, Carlo / Ceccato, Tommaso / Bernasconi, Valentina / Lanocita, Rodolfo / Cascella, Tommaso / Claps, Melanie / Giannatempo, Patrizia / Zimatore, Matteo / Cattaneo, Laura / Biasoni, Davide / Montanari, Emanuele / Nicolai, Nicola

Clinical genitourinary cancer

2024 Volume 22, Issue 2, Page(s) 544–548

Abstract: Introduction: Surveillance is the standard management in low-risk cN0 penile squamous cell carcinoma (peSCC) patients. However, no previous analysis focused on early and long-term outcomes of these patients. We report on main oncological outcomes of a ... ...

Abstract	Introduction: Surveillance is the standard management in low-risk cN0 penile squamous cell carcinoma (peSCC) patients. However, no previous analysis focused on early and long-term outcomes of these patients. We report on main oncological outcomes of a large series of low-risk cN0 peSCC patients. Patients and methods: Between 1980 and 2017 included, 93 evaluable consecutive low-risk (ie, pT1a G1 cN0M0) peSCC patients underwent primary tumor surgery and either observation (74) or dynamic sentinel node biopsy (DSNB) (19) following a clinical diagnosis of T1 in 66 (71%), T2 in 15 (16.1%) and Tx in 12 (12.9%) patients, respectively. The statistical significance of differences in medians and proportions was tested with the Kruskal-Wallis and chi-square tests. Kaplan-Meier plots illustrated 5-year inguinal relapse (IR)-free survival rates. Results: Median age was 60 years (IQR: 50-69 years). Median follow-up was 92 months (IQR 54-133 months). Surveillance was more frequently adopted in clinical (c)T1 than in cT2 tumors (79.7% vs. 36.8%). None of 19 patients who had DSNB had nodal metastasis. Overall, 7 (7.5%) out of 93 pT1aG1cN0 peSCC patients had IR after a median interval of 9 months. Of note, 1 patient only relapsed after 12 months of surveillance. After stratification according to IR, relapses occurred more frequently in younger patients (59 vs. 64 years, P < .001). The 5-year IR-free survival rates for the entire cohort was 92% (95% Confidence interval [CI] 87-98%). Conclusions: Observation is a safe and effective management for low-risk peSCC patients. Younger patients may be offered a mini-invasive staging as an alternative.
MeSH term(s)	Male ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Sentinel Lymph Node Biopsy ; Penile Neoplasms/pathology ; Carcinoma, Squamous Cell/pathology ; Neoplasm Staging
Language	English
Publishing date	2024-01-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	2225121-2
ISSN	1938-0682 ; 1558-7673
ISSN (online)	1938-0682
ISSN	1558-7673
DOI	10.1016/j.clgc.2024.01.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Bilateral inguinal lymph-node dissection vs. unilateral inguinal lymph-node dissection and dynamic sentinel node biopsy in clinical N1 squamous cell carcinoma of the penis.

Nazzani, Sebastiano / Catanzaro, Mario / Biasoni, Davide / Maccauro, Marco / Stagni, Silvia / Torelli, Tullio / Macchi, Alberto / Bernasconi, Valentina / Taverna, Alessandra / Sessa, Dario / Lorenzoni, Alice / Piva, Luigi / Lanocita, Rodolfo / Cascella, Tommaso / Cattaneo, Laura / Montanari, Emanuele / Salvioni, Roberto / Nicolai, Nicola

Urologic oncology

2023 Volume 41, Issue 4, Page(s) 210.e1–210.e8

Abstract: Introduction: To evaluate the role of unilateral inguinal lymph-node dissection (ILND) plus contralateral dynamic sentinel node biopsy (DSNB) vs. bilateral ILND in clinical N1 (cN1) penile squamous cell carcinoma (peSCC) patients.: Material and ... ...

Abstract	Introduction: To evaluate the role of unilateral inguinal lymph-node dissection (ILND) plus contralateral dynamic sentinel node biopsy (DSNB) vs. bilateral ILND in clinical N1 (cN1) penile squamous cell carcinoma (peSCC) patients. Material and methods: Within our institutional database (1980-2020, included), we identified 61 consecutive cT1-4 cN1 cM0 patients with histological confirmed peSCC who underwent either unilateral ILND plus DSNB (26) or bilateral ILND (35). Results: Median age was 54 years (Interquartile range [IQR]: 48-60 years). Median follow-up was 68 months (IQR 21-105 months). Most patients had pT1 (23 %) or pT2 (54.1%), as well as G2 (47.5%) or G3 (23%) tumors, while lymphovascular invasion (LVI) was present in 67.1% of cases. Considering a cN1 and a cN0 groin, overall 57 out of 61 patients (93.5%) had nodal disease in the cN1 groin. Conversely, only 14 out of 61 patients (22.9%) had nodal disease in the cN0 groin. 5-year IR-free survival was 91% (Confidence interval [CI] 80%-100%) for bilateral ILND group and 88% (CI 73%-100%) for the ipsilateral ILND plus DSNB group (P-value 0.8). Conversely, 5-year CSS was 76% (CI 62%-92%) for bilateral ILND group and 78% (CI 63%-97%) for the ipsilateral ILND plus contralateral DSNB group (P-value 0.9). Conclusions: In patients with cN1 peSCC the risk of occult contralateral nodal disease is comparable to cN0 high risk peSCC and the gold standard, namely bilateral ILND, may be replaced by unilateral ILND and contralateral DSNB without affecting positive node detection, IRRs and CSS.
MeSH term(s)	Male ; Humans ; Middle Aged ; Sentinel Lymph Node Biopsy ; Lymph Node Excision ; Lymph Nodes/surgery ; Lymph Nodes/pathology ; Penis/pathology ; Penile Neoplasms/surgery ; Penile Neoplasms/pathology ; Carcinoma, Squamous Cell/surgery ; Carcinoma, Squamous Cell/pathology ; Neoplasm Staging
Language	English
Publishing date	2023-03-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	1336505-8
ISSN	1873-2496 ; 1078-1439
ISSN (online)	1873-2496
ISSN	1078-1439
DOI	10.1016/j.urolonc.2023.02.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4817: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy.

Marchioni, Michele / Nazzani, Sebastiano / Preisser, Felix / Bandini, Marco / Karakiewicz, Pierre I

Expert review of anticancer therapy

2018 Volume 18, Issue 4, Page(s) 377–387

Abstract: Introduction: In patients with muscle invasive or Bacillus Calmette-Guérin refractory urothelial carcinoma of the urinary bladder (UCUB) radical cystectomy represents the standard of care. However, a proportion of patients experience disease progression, ...

Abstract	Introduction: In patients with muscle invasive or Bacillus Calmette-Guérin refractory urothelial carcinoma of the urinary bladder (UCUB) radical cystectomy represents the standard of care. However, a proportion of patients experience disease progression, local recurrence and/or metastatic disease. Areas covered: This review provides an overview of available therapeutic strategies after radical cystectomy and examines ongoing clinical trials including cytotoxic chemotherapy and immunotherapy. Expert commentary: Cytotoxic chemotherapy offers limited benefit in UCUB patients. However, the recent introduction of immunotherapy provides new hope for durable responses or possibly complete cures.
MeSH term(s)	Antineoplastic Agents/administration & dosage ; BCG Vaccine/administration & dosage ; Carcinoma, Transitional Cell/pathology ; Carcinoma, Transitional Cell/therapy ; Combined Modality Therapy ; Cystectomy/methods ; Disease Progression ; Humans ; Immunotherapy/methods ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/therapy
Chemical Substances	Antineoplastic Agents ; BCG Vaccine
Language	English
Publishing date	2018-02-15
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2112544-2
ISSN	1744-8328 ; 1473-7140
ISSN (online)	1744-8328
ISSN	1473-7140
DOI	10.1080/14737140.2018.1439744
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5907: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Bladder recurrence of primary upper tract urinary carcinoma following nephroureterectomy, and risk of upper urinary tract recurrence after ureteral stent positioning in patients with primary bladder cancer.

Mistretta, Francesco A / Carrion, Diego M / Nazzani, Sebastiano / Vásquez, Juan L / Fiori, Cristian / De Cobelli, Ottavio / Porpiglia, Francesco / Esperto, Francesco

Minerva urologica e nefrologica = The Italian journal of urology and nephrology

2019 Volume 71, Issue 3, Page(s) 191–200

Abstract: Upper tract urinary carcinoma (UTUC) and bladder cancer (BCa) share similar biological, histological and pathological characteristics. These resemblances could explain the high rate of synchronous and metachronous tumors affecting both upper urinary ... ...

Abstract	Upper tract urinary carcinoma (UTUC) and bladder cancer (BCa) share similar biological, histological and pathological characteristics. These resemblances could explain the high rate of synchronous and metachronous tumors affecting both upper urinary tract and bladder. In patients affected by primary UTUC bladder recurrence is quite common and it represents one of the major concerns during the follow-up of patients who underwent radical nephroureterectomy. Conversely, UTUC recurrence after primary non-muscular invasive BCa is a relatively rare event. Moreover, there is no clear evidence on whether the use of Double-J stenting as drainage in patients affected by BCa increases the risk of UTUC recurrence. The aim of the current study was to summarize the most recent evidence regarding the bladder recurrence after UTUC surgical treatment, and the UTUC recurrence after stent positioning in patients affected by primary BCa.
MeSH term(s)	Drainage ; Humans ; Neoplasm Recurrence, Local ; Neoplasms, Second Primary/surgery ; Nephroureterectomy ; Stents ; Ureteral Obstruction/etiology ; Ureteral Obstruction/surgery ; Urinary Bladder Neoplasms/complications ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/surgery ; Urologic Neoplasms/complications ; Urologic Neoplasms/pathology ; Urologic Neoplasms/surgery
Language	English
Publishing date	2019-01-17
Publishing country	Italy
Document type	Journal Article ; Review
ZDB-ID	632505-1
ISSN	1827-1758 ; 0393-2249 ; 0026-4989
ISSN (online)	1827-1758
ISSN	0393-2249 ; 0026-4989
DOI	10.23736/S0393-2249.19.03311-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 16: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Renal tumor biopsy in patients with cT1b-T4-M0 disease susceptible to radical nephrectomy: analysis of safety, accuracy and clinical impact on definitive management.

Nazzani, Sebastiano / Zaborra, Carlotta / Biasoni, Davide / Catanzaro, Mario / Macchi, Alberto / Stagni, Silvia / Tesone, Antonio / Torelli, Tullio / Lanocita, Rodolfo / Cascella, Tommaso / Morosi, Carlo / Spreafico, Carlo / Colecchia, Maurizio / Marchianò, Alfonso / Montanari, Emanuele / Salvioni, Roberto / Nicolai, Nicola

Scandinavian journal of urology

2022 , Page(s) 1–6

Abstract: Purpose: Renal tumor biopsy was provided in patients candidate to radical nephrectomy for a renal mass ≥4 cm, to evaluate treatment deviation.: Methods: Between 2008 and 2017, 102 patients with a solid renal mass ≥4 cm with no distant metastases ... ...

Abstract	Purpose: Renal tumor biopsy was provided in patients candidate to radical nephrectomy for a renal mass ≥4 cm, to evaluate treatment deviation. Methods: Between 2008 and 2017, 102 patients with a solid renal mass ≥4 cm with no distant metastases underwent preliminary renal tumor biopsy. We investigated the proportion of patients who proceeded with radical nephrectomy, variables predicting non-renal cell carcinoma (RCC) and concordance between biopsy findings and definitive pathology. Results: Median tumor size was 70 mm (IQR 55-110). Clinical stage was cT1b in 41, cT2 in 33, cT3 in 25 and cT4 in three patients. A median of three (IQR 2-3) renal tumor biopsies were taken with 16/18 Gauge needles in 97% of cases. Clavien grade I complications occurred in five cases. Malignant tumors were documented in 84 patients: 78 RCCs and six non-RCCs. Fifteen biopsies documented oncocytoma and three were non-diagnostic. Grade was reported in 50 RCCs: 42 (84%) were low and eight (16%) high grade. Eighty-three patients proceeded with radical nephrectomy; six non-RCC malignant tumors underwent combined and/or intensified treatment; 13 of 15 patients with oncocytoma did not undergo radical nephrectomy (eight underwent observation). Definitive pathology confirmed diagnosis in all cases. Grade concordance was 84%, considering two tiers (high vs low grade). No preoperative clinical variable predicted definitive pathology. Conclusions: Renal tumor biopsy is a safe procedure that leads to radical nephrectomy in most tumors ≥4 cm. Nonetheless, 20% of patients exhibited non-RCC histology. Renal tumor biopsy should be considered in this setting.
Language	English
Publishing date	2022-06-29
Publishing country	England
Document type	Journal Article
ZDB-ID	2701936-6
ISSN	2168-1813 ; 2168-1805
ISSN (online)	2168-1813
ISSN	2168-1805
DOI	10.1080/21681805.2022.2092549
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 601: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy.

Nicolai, Nicola / Nazzani, Sebastiano / Tesone, Antonio / Macchi, Alberto / Piva, Luigi / Salvioni, Roberto / Stagni, Silvia / Torelli, Tullio / Agostini, Edoardo / Celso, Francesco / Giannatempo, Patrizia / Procopio, Giuseppe / Avuzzi, Barbara / Lanocita, Rodolfo / Cattaneo, Laura / Catanzaro, Mario / Biasoni, Davide

Tumori

2022 Volume 109, Issue 4, Page(s) 379–386

Abstract: Introduction: Patients with stage II germ-cell tumours (GCT) usually undergo radiotherapy (seminoma only) or chemotherapy. Both strategies display a recognised risk of long-term side effects. We evaluated retroperitoneal lymph node dissection (RPLND) as ...

Abstract	Introduction: Patients with stage II germ-cell tumours (GCT) usually undergo radiotherapy (seminoma only) or chemotherapy. Both strategies display a recognised risk of long-term side effects. We evaluated retroperitoneal lymph node dissection (RPLND) as exclusive treatment in stage II GCT. Methods: Between 2008 and 2019 included, 66 selected stage II GCT patients underwent primary open (O-) or laparoscopic (L-)RPLND. Type of procedure and extent of dissection, operative time, node rescue, hospital stay, complications (according to Clavien-Dindo), administration of chemotherapy, relapse and site of relapse were evaluated. Results: Five patients had pure testicular seminoma. Nineteen (28.8%) had raised markers prior to RPLND; 48 (72.7%), 16 (24.2%) and two (3.0%) were stage IIA, IIB and IIC, respectively. O-RPLND and unilateral L-RPLND were 36 and 30 respectively. Six stage II A patients (12.5%) had negative nodes. Four patients underwent immediate adjuvant chemotherapy. One patient was lost at follow-up. After a median follow-up of 29 months, 48 (77.4%) of the 62 patients undergoing RPLND alone remained recurrence-free; one patient had an in-field recurrence following a bilateral dissection. According to procedure, number of rescued nodes (O-RPLND: 25. IQR 21-31; L-RPLND: 20, IQR 15-26; p: 0.001), hospital stay (L-RPLND: 3 days, IQR 3-4; O-RPLND: 6 days, IQR 5-8; p: .001) and grade ≥2 complications (L-RPLND 7%, O-RPLND 22%; p: 0.1) were the only significant differences. Conclusion: Primary RPLND is safe in stage II GCT, including seminoma, and may warrant a cure rate greater than 70%. When feasible, L-RPLND may be as effective as O-RPLND with better tolerability.
MeSH term(s)	Male ; Humans ; Seminoma/pathology ; Testicular Neoplasms/radiotherapy ; Testicular Neoplasms/surgery ; Testicular Neoplasms/drug therapy ; Treatment Outcome ; Retrospective Studies ; Neoplasm Recurrence, Local/pathology ; Lymph Node Excision/methods ; Neoplasms, Germ Cell and Embryonal/surgery ; Neoplasms, Germ Cell and Embryonal/etiology ; Neoplasms, Germ Cell and Embryonal/pathology ; Laparoscopy/adverse effects ; Laparoscopy/methods ; Retroperitoneal Space/pathology ; Retroperitoneal Space/surgery ; Neoplasm Staging
Language	English
Publishing date	2022-08-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	280962-x
ISSN	2038-2529 ; 0300-8916
ISSN (online)	2038-2529
ISSN	0300-8916
DOI	10.1177/03008916221112697
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.43: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 287: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito